Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5OY70)

• Drug Name: Iron Dextran Drug Info
• Synonyms: Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1)

Indication

Disease Entry	ICD 11	Status	REF
Iron-deficiency anemia	3A00	Approved	[1]

• Therapeutic Class: Iron Supplement
• Cross-matching ID:
  PubChem CID: 105075
  CAS Number: CAS 9004-66-4
  TTD Drug ID: DM5OY70

Molecule-Related Drug Atlas

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[4]
Iron	DMAP8MV	Anemia of prematurity		Approved	[2]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[5]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[6]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[7]
GBT021601	DMD3C21	Sickle-cell disorder	3A51	Phase 2/3	[8]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[9]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[10]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[11]
OXY-111A	DMTH75R	Cardiovascular disease	BA00-BE2Z	Phase 1/2	[12]

Drug(s) Affected By Putative hydrolase DDAH2 (DDAH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[18]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[19]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[20]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Activator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Putative hydrolase DDAH2 (DDAH2)	OT8Q40G2	DDAH2_HUMAN	Gene/Protein Processing	[3]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010787.
• [2] Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
• [3] Tetramethylpyrazine alleviates iron overload damage in vascular endothelium via upregulating DDAHII expression. Toxicol In Vitro. 2020 Jun;65:104817. doi: 10.1016/j.tiv.2020.104817. Epub 2020 Mar 2.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
• [6] Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
• [7] Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
• [8] GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
• [9] A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
• [10] A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
• [11] 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
• [12] Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
• [13] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [14] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [15] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [16] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [17] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [18] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [19] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [20] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [21] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [22] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.